½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1468293

¹é½Å Àü´Þ ±â±â ½ÃÀå º¸°í¼­ : ±â±â, Åõ¿© °æ·Î, ÃÖÁ¾»ç¿ëÀÚ, Áö¿ªº°(2024-2032³â)

Vaccine Delivery Devices Market Report by Device, Route of Administration, End User, and Region 2024-2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: IMARC | ÆäÀÌÁö Á¤º¸: ¿µ¹® 138 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀå ±Ô¸ð´Â 2023³â 75¾ï ´Þ·¯¿¡ ´ÞÇß½À´Ï´Ù. ÇâÈÄ IMARC GroupÀº 2032³â±îÁö ½ÃÀå ±Ô¸ð°¡ 2024-2032³â »çÀÌ 6.61%ÀÇ ¿¬Æò±Õ ¼ºÀå·ü(CAGR)·Î 135¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óÇÏ°í ÀÖ½À´Ï´Ù.

¹é½ÅÀº ¼¼±Õ¼º Áúº´¿¡ ´ëÇÑ ½ÅüÀÇ ¸é¿ª ¹ÝÀÀÀ» ÀÚ±ØÇÏ¿© ¼¼±Õ¼º Áúº´À¸·ÎºÎÅÍ °³ÀÎÀ» º¸È£ÇÏ´Â µ¥ »ç¿ëµÇ´Â »ý¹°ÇÐÀû ¹°ÁúÀÔ´Ï´Ù. ƯÁ¤ °£°ÝÀ¸·Î Åõ¿©ÇÔÀ¸·Î½á ¸é¿ª ü°è°¡ ħÀÔ Ç׿ø¿¡ ´ëÇÑ Ç×ü¸¦ »ý¼ºÇϵµ·Ï µ½½À´Ï´Ù. ¸®Æ÷Á», ¸¶ÀÌÅ©·Î½ºÇǾî, ³ª³ëÀÔÀÚ, µ§µå¸®¸Ó, ¹Ì¼¿È­ ½Ã½ºÅÛ, ¸é¿ª ÀÚ±Ø º¹ÇÕü(ISCOM), ½Ä¹° À¯·¡ ¹ÙÀÌ·¯½º µîÀ» ÅëÇØ Ã¼³»¿¡ Åõ¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÇöÀç Àü ¼¼°èÀûÀ¸·Î Àü¿°º´ÀÌ À¯ÇàÇÏ°í Àֱ⠶§¹®¿¡ ¹é½Å Àü´Þ ±â±âÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

¹é½Å Àü´Þ ±â±â ½ÃÀå µ¿Çâ:

¸¶ÀÌÅ©·Î´Ïµé ¹× ÀÏ·ºÆ®·ÎÆ÷·¹À̼ǰú °°Àº ¹é½ÅÀÇ Ã¼°èÀûÀÎ Àü´Þ ±â¼ú ¹ßÀüÀº ½ÃÀåÀ» ÁÖµµÇÏ´Â Áß¿äÇÑ ¿ä¼Ò Áß ÇϳªÀÔ´Ï´Ù. ¶ÇÇÑ, ¹Ù´Ã¿¡ Âñ¸®´Â ºÎ»ó °¨¼Ò, ¹é½Å Ç׿ø Åõ¿©·® °¨¼Ò, ¹é½Å ¸é¿ª¿ø¼º Çâ»óÀ¸·Î ÀÎÇØ ¹Ù´ÃÀ» »ç¿ëÇÏÁö ¾Ê´Â Àü´Þ ½Ã½ºÅÛÀÇ »ç¿ëÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ´Â ¹é½Å ºÎ¹®ÀÇ ¿¬±¸ Áõ°¡¿Í Àü ¼¼°èÀûÀ¸·Î »õ·Î¿î ¹é½Å Àü´Þ ±â±â°¡ °³¹ßµÇ°í ÀÖ´Â °Í°ú ÇÔ²² ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¢±¹ Á¤ºÎ´Â ¹é½ÅÀ¸·Î ¿¹¹æ °¡´ÉÇÑ Áúº´À¸·Î ÀÎÇÑ Àå¾Ö¿Í »ç¸ÁÀ» ¿¹¹æÇϱâ À§ÇØ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥À» ÃßÁøÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ¿Í ÇÔ²² ºñÁ¤ºÎ±â±¸(NGO)ÀÇ ´Ù¾çÇÑ ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ ¹× Ä·ÆäÀο¡ ´ëÇÑ ÅõÀÚ°¡ Àü ¼¼°èÀûÀ¸·Î È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÁÖ¿ä ½ÃÀå ÁøÀÔ ±â¾÷µéÀº µ¶¼ºÀ» ÁÙ¿© ¹é½ÅÀÇ Ä¡·áÀû °¡Ä¡¸¦ ³ôÀÌ´Â »õ·Î¿î Àü´Þ ±â¼ú¿¡ ÁýÁßÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ëÀÎ Àα¸ Áõ°¡·Î ÀÎÇÑ ÀÇ·á ºÎ¹®ÀÇ È®´ë¿Í ÀÇ·á Á¦Ç° ¹× ¼­ºñ½º¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ ¿ëÀÌÇØÁü¿¡ µû¶ó ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª¹ÙÀÌ·¯½º°¨¿°Áõ-19(COVID-19)ÀÇ ¹ß»ýÀ¸·Î ¹é½Å Àü´Þ ±â±âÀÇ ¼¼°è ¸ÅÃâÀÌ Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­¿¡¼­ ´Ù·ç´Â ÁÖ¿ä Áú¹®µé

  • 2023³â ¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀå ±Ô¸ð´Â?
  • 2024-2032³â ¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀåÀÇ ¿¹»ó ¼ºÀå·üÀº?
  • ¹é½Å Àü´Þ ±â±â ¼¼°è ½ÃÀåÀ» À̲ô´Â ÁÖ¿ä ¿äÀÎÀº ¹«¾ùÀΰ¡?
  • COVID-19°¡ ¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀº?
  • ¼¼°è ¹é½Å Àü´Þ ±â±âº° ¹é½Å Àü´Þ ±â±â ½ÃÀå ÇöȲÀº?
  • Åõ¿© °æ·Îº° ¹é½Å Àü´Þ ±â±â ¼¼°è ½ÃÀå ÇöȲÀº?
  • ¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀåÀÇ ÃÖÁ¾»ç¿ëÀÚº° ºÐ·ù´Â?
  • ¹é½Å Àü´Þ ±â±â ¼¼°è ½ÃÀå¿¡¼­ ÁÖ¿ä Áö¿ªÀº ¾îµðÀΰ¡?
  • ¼¼°è ¹é½Å Àü´Þ ±â±â ½ÃÀåÀÇ ÁÖ¿ä ÁøÀÔ ±â¾÷Àº?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹üÀ§¿Í Á¶»ç ¹æ¹ý

  • Á¶»ç ¸ñÀû
  • ÀÌÇØ°ü°èÀÚ
  • µ¥ÀÌÅÍ ¼Ò½º
    • 1Â÷ Á¤º¸
    • 2Â÷ Á¤º¸
  • ½ÃÀå ÃßÁ¤
    • »óÇâ½Ä Á¢±Ù
    • ÇÏÇâ½Ä Á¢±Ù
  • Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ¼Ò°³

  • °³¿ä
  • ÁÖ¿ä »ê¾÷ µ¿Çâ

Á¦5Àå ¹é½Å Àü´Þ ±â±â ¼¼°è ½ÃÀå

  • ½ÃÀå °³¿ä
  • ½ÃÀå ½ÇÀû
  • COVID-19ÀÇ ¿µÇâ
  • ½ÃÀå ¿¹Ãø

Á¦6Àå ½ÃÀå ³»¿ª : ±â±âº°

  • ÁÖ»ç±â
  • Á¦Æ® ÀÎÁ§ÅÍ
  • ±âŸ

Á¦7Àå ½ÃÀå ³»¿ª : Åõ¿© °æ·Îº°

  • ±ÙÀ°³» ¹é½Å Á¢Á¾
  • Çdz» ¹é½Å Á¢Á¾
  • ÇÇÇÏ ¹é½Å Á¢Á¾
  • ±âŸ

Á¦8Àå ½ÃÀå ³»¿ª : ÃÖÁ¾»ç¿ëÀÚº°

  • º´¿ø
  • Ŭ¸®´Ð
  • ±âŸ

Á¦9Àå ½ÃÀå ³»¿ª : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • Çѱ¹
    • È£ÁÖ
    • Àεµ³×½Ã¾Æ
    • ±âŸ
  • À¯·´
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ½ÃÀå µ¿Çâ
    • ½ÃÀå ³»¿ª : ±¹°¡º°
    • ½ÃÀå ¿¹Ãø

Á¦10Àå SWOT ºÐ¼®

  • °³¿ä
  • °­Á¡
  • ¾àÁ¡
  • ±âȸ
  • À§Çù

Á¦11Àå ¹ë·ùüÀÎ ºÐ¼®

Á¦12Àå Porter's Five Forces ºÐ¼®

  • °³¿ä
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • °æÀï Á¤µµ
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • ´ëüǰÀÇ À§Çù

Á¦13Àå °¡°Ý ºÐ¼®

Á¦14Àå °æÀï »óȲ

  • ½ÃÀå ±¸Á¶
  • ÁÖ¿ä ±â¾÷
  • ÁÖ¿ä ±â¾÷ °³¿ä
    • 3M Company
    • Becton Dickinson and Company
    • Enesi Pharma Limited
    • Gerresheimer AG
    • INOVIO Pharmaceuticals
    • NanoPass
    • Panacea Biotec Pharma Limited(Panacea Biotec)
    • Pharmajet Inc.
    • Schott AG(Carl-Zeiss-Stiftung)
    • Terumo Corporation
    • Vaxxas
ksm 24.05.09

The global vaccine delivery devices market size reached US$ 7.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 13.5 Billion by 2032, exhibiting a growth rate (CAGR) of 6.61% during 2024-2032.

A vaccine is a biological substance used to protect individuals from bacterial illnesses by stimulating the immune response of the body against the disease. It helps the immune system to produce antibodies against the invading antigens when given at specific intervals. It can be delivered in the body through liposomes, microspheres, nanoparticles, dendrimers, micellar systems, immune stimulating complexes (ISCOMs), and plant-derived viruses. At present, there is a rise in the utilization of vaccine delivery devices due to the growing prevalence of infectious diseases across the globe.

Vaccine Delivery Devices Market Trends:

Technological advancements in the systematic delivery of vaccines, such as micro-needles and electroporation, represent one of the key factors driving the market. Moreover, there is an increase in the utilization of needle-free delivery systems as they decrease needle stick injuries and the vaccine antigen dose and enhance the vaccine immunogenicity. This, along with the rising research in the field of vaccines and the development of new vaccine delivery devices around the world, is propelling the growth of the market. In addition, governments of several countries are promoting immunization programs to prevent disabilities and deaths from vaccine-preventable diseases. This, coupled with the growing investments by non-governmental organizations (NGOs) for various vaccination programs and campaigns globally, is positively influencing the market. Besides this, key market players are focusing on novel delivery technologies that increase the therapeutic value of vaccines by reducing toxicity. Additionally, the expanding healthcare sector due to the increasing geriatric population and easy access to medical products and services is bolstering the market growth. Furthermore, the outbreak of coronavirus disease (COVID-19) is augmenting the sales of vaccine delivery devices worldwide.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global vaccine delivery devices market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on device, route of administration and end user.

Breakup by Device:

Syringes

Jet Injectors

Others

Breakup by Route of Administration:

Intramuscular Vaccination

Intradermal Vaccination

Subcutaneous Vaccination

Others

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being 3M Company, Becton Dickinson and Company, Enesi Pharma Limited, Gerresheimer AG, INOVIO Pharmaceuticals, NanoPass, Panacea Biotec Pharma Limited (Panacea Biotec), Pharmajet Inc., Schott AG (Carl-Zeiss-Stiftung), Terumo Corporation and Vaxxas.

Key Questions Answered in This Report

  • 1. What was the size of the global vaccine delivery devices market in 2023?
  • 2. What is the expected growth rate of the global vaccine delivery devices market during 2024-2032?
  • 3. What are the key factors driving the global vaccine delivery devices market?
  • 4. What has been the impact of COVID-19 on the global vaccine delivery devices market?
  • 5. What is the breakup of the global vaccine delivery devices market based on the device?
  • 6. What is the breakup of the global vaccine delivery devices market based on the route of administration?
  • 7. What is the breakup of the global vaccine delivery devices market based on end user?
  • 8. What are the key regions in the global vaccine delivery devices market?
  • 9. Who are the key players/companies in the global vaccine delivery devices market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Vaccine Delivery Devices Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Device

  • 6.1 Syringes
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Jet Injectors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Intramuscular Vaccination
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intradermal Vaccination
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Subcutaneous Vaccination
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Hospitals
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Clinics
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 3M Company
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Becton Dickinson and Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Enesi Pharma Limited
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Gerresheimer AG
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 Financials
    • 14.3.5 INOVIO Pharmaceuticals
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 NanoPass
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Panacea Biotec Pharma Limited (Panacea Biotec)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Pharmajet Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Schott AG (Carl-Zeiss-Stiftung)
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 SWOT Analysis
    • 14.3.10 Terumo Corporation
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis
    • 14.3.11 Vaxxas
      • 14.3.11.1 Company Overview
      • 14.3.11.2 Product Portfolio
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦